Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13

被引：0

作者：

Park, Won ^{[1
]}

Miranda, Pedro ^{[2
,3
]}

Brzosko, Marek ^{[4
]}

Wiland, Piotr ^{[5
]}

Gutierrez-Urena, Sergio ^{[6
]}

Mikazane, Helena ^{[7
]}

Lee, Yeon-Ah ^{[8
]}

Smiyan, Svitlana ^{[9
]}

Lim, Mie-Jin ^{[1
]}

Kadinov, Vladimir ^{[10
]}

Abud-Mendoza, Carlos ^{[11
,12
]}

Son, YoungKi ^{[13
]}

Yoo, Dae-Hyun ^{[14
]}

Braun, Juergen ^{[15
]}

机构：

[1] Inha Univ Hosp, Inchon, South Korea

[2] Univ Chile, Santiago, Chile

[3] Ctr Estudios Reumatol, Santiago, Chile

[4] Pomeranian Med Univ, Dept Rheumatol & Internal Dis, Szczecin, Poland

[5] Med Univ Wroclaw, Wroclaw, Poland

[6] Antiguo Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico

[7] Outpatient Clin ORTO, Riga, Latvia

[8] Kyung Hee Univ, Seoul, South Korea

[9] Ternopil Univ Hosp, Municipal Inst Ternopil Reg Council, Ternopol, Ukraine

[10] Multiprofile Hosp Act Treatment Sv Marina, Varna, Bulgaria

[11] Univ Autonoma San Luis Potosi, Hosp Cent, San Luis Potosi, Mexico

[12] Univ Autonoma San Luis Potosi, Fac Med, San Luis Potosi, Mexico

[13] CELLTRION, Inchon, South Korea

[14] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea

[15] Rheumazentrum Ruhrgebiet, Herne, Germany

来源：

ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

L15

引用

页码：3326 / 3326

页数：1

共 50 条

[41] Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
Jahnsen, Jorgen
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 322 - 329
[42] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
Parigi, Tommaso Lorenzo
D'Amico, Ferdinando
Peyrin-Biroulet, Laurent
Danese, Silvio
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
[43] EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS
Privitera, Giuseppe
Pugliese, Daniela
Tolusso, Barbara
Gremese, Elisa
Papa, Alfredo
Papparella, Luigi Giovanni
Gasbarrini, Antonio
Rapaccini, Gian Lodovico
Guidi, Luisa
Armuzzi, Alessandro
GASTROENTEROLOGY, 2020, 158 (06) : S462 - S462
[44] EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS
Privitera, G.
Pugliese, D.
Tolusso, B.
Gremese, E.
Papa, A.
Papparella, L. G.
Gasbarrini, A.
Rapaccini, G. L.
Guidi, L.
Armuzzi, A.
DIGESTIVE AND LIVER DISEASE, 2020, 52 : S10 - S11
[45] Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar
Mahmmod, S.
Schultheiss, J. P. D.
Tan, A. C. I. T. L.
Lutgens, M. W. M. D.
Gilissen, L. P. L.
Mahmmod, N.
van der Meulen-de Jong, A. E.
Dijkstra, G.
van Bodegraven, A. A.
Oldenburg, B.
Fidder, H. H.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S316 - S317
[46] Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
Gisondi, P.
Virga, C.
Piaserico, S.
Meneguzzo, A.
Odorici, G.
Conti, A.
Girolomoni, G.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 397 - 398
[47] A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
Campochiaro, Corrado
Tomelleri, Alessandro
Sartorelli, Silvia
Sembenini, Camilla
Papa, Maurizio
Fallanca, Federico
Picchio, Maria
Cavalli, Giulio
De Cobelli, Francesco
Baldissera, Elena
Dagna, Lorenzo
FRONTIERS IN MEDICINE, 2021, 8
[48] Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report
Arginelli, Federica
Paganelli, Alessia
Rongioletti, Franco
Pellacani, Giovanni
Conti, Andrea
DERMATOLOGIC THERAPY, 2018, 31 (02)
[49] A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitis
Ben-Horin, S.
Leszczyszyn, J.
Dudkowiak, R.
Lahat, A.
Gawdis-Wojnarska, B.
Pukitis, A.
Horynski, M.
Farkas, K.
Kierkus, J.
Kowalski, M.
Ye, B. D.
Reinisch, W.
Lee, S. J.
Kim, S. H.
Kim, M. R.
Kim, Y. A.
Kim, H. N.
Schreiber, S.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S021 - S022
[50] Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance
Scherlinger, Marc
Germain, Vincent
Labadie, Celine
Barnetche, Thomas
Truchetet, Marie-Elise
Bannwarth, Bernard
Mehsen-Cetre, Nadia
Richez, Christophe
Schaeverbeke, Thierry
JOINT BONE SPINE, 2018, 85 (05) : 561 - 567

← 1 2 3 4 5 →